Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimustine + teniposide
- Development stage
- Preclinical
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Nimustine + teniposide is a combination chemotherapy regimen used primarily in the treatment of malignant gliomas, including glioblastoma. Nimustine (ACNU) is a nitrosourea alkylating agent that works by cross-linking DNA strands and inhibiting DNA replication and transcription. Teniposide (VM26) is a topoisomerase II inhibitor that induces DNA strand breaks by stabilizing the enzyme-DNA complex during replication. The combination has been studied as both first-line and salvage therapy for glioblastoma, particularly after failure of standard temozolomide-based regimens. Clinical studies indicate moderate efficacy but significant hematologic toxicity, especially myelosuppression[1][2][3][6].
- Other names
- ACNU + VM26
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on nimustine + teniposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimustine + teniposide.